Biberarch an der Riss, Germany

Detlef Mohr



 

Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 8(Granted Patents)


Location History:

  • Biberach an der Riss, DE (2014)
  • Biberarch an der Riss, DE (2019 - 2020)

Company Filing History:


Years Active: 2014-2020

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Detlef Mohr

Introduction

Detlef Mohr is a notable inventor based in Biberach an der Riss, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of oral suspension formulations. With a total of 3 patents to his name, his work has had a meaningful impact on the industry.

Latest Patents

Among his latest patents, Detlef Mohr has developed an oral suspension comprising telmisartan. This drinkable pharmaceutical solution includes telmisartan or a pharmaceutically acceptable salt, hydrate, or polymorph thereof, with a concentration of 1 to 10 mg/ml. The solution is designed to have a pH of 10. Another patent focuses on a pharmaceutical solution with a pH value of 10 or higher that contains an angiotensin II receptor antagonist. This formulation incorporates one or more sugar alcohols present at a total concentration of 40 wt. % to 70 wt. %.

Career Highlights

Detlef Mohr has worked with prominent companies in the pharmaceutical sector, including Boehringer Ingelheim Vetmedica, Inc. and Boehringer Ingelheim Vetmedica GmbH. His experience in these organizations has allowed him to refine his expertise in drug formulation and development.

Collaborations

Detlef has collaborated with several professionals in his field, including Stefan Johannes Lehner and Stefan Lehner. These partnerships have contributed to the advancement of his innovative projects.

Conclusion

Detlef Mohr's contributions to pharmaceutical innovations, particularly in oral suspension formulations, highlight his role as a significant inventor in the industry. His patents reflect a commitment to improving drug delivery systems, which can enhance patient care and treatment outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…